Citryll, a clinical-stage biotech company developing therapeutics to treat immune-mediated inflammatory diseases, has appointed Eduardo Bravo as CEO and Tim Schenk as chief business officer. The appointments come at a time when the company has completed the healthy volunteer studies for its lead Neutrophil Extracellular Trap-targeting antibody, CIT-013, and is transitioning into the next stage…